Public evidence
Publicly accessible research, trial, regulatory, conference, corporate, and institutional records, with source and date context retained.
TRUST & DATA USE
Clear evidence boundaries before analysis begins.
Enterprise trust starts with stating what evidence may enter the work, how machine assistance and human review interact, and who retains decision authority.
Evidence use is permissioned and decision-specific.
The public website describes the categories OncoLattice may use; each engagement still requires a defined scope and the appropriate rights.
Licensed or de-identified evidence
Clinical or other non-public evidence only where it is appropriately licensed, de-identified, permitted, and fit for the decision.
Sponsor or CRO context
Non-confidential context supplied for a bounded question. Confidential or patient-level material should not be submitted through the public website.
Machine assistance accelerates the work; review governs the claim.
The evidence record, assumptions, conflicts, unknowns, confidence boundary, and next validation remain visible to the decision team.
Machine-assisted retrieval and comparison
Automation may support retrieval, normalization, comparison, and monitoring. It does not create decision authority.
Human and clinical review
Material interpretations are reviewed for source fit, clinical plausibility, contradiction, and scope before they become a decision brief.
Sponsor-owned decision
The sponsor and its authorized medical, regulatory, legal, and execution partners retain the final decision and validation responsibilities.
No claim of patient access or contactability, institutional or regulatory endorsement, ownership of public evidence, autonomous clinical decision-making, universal data coverage, certification, guaranteed outcome, or replacement of sponsor governance or CRO execution.
Outputs are for strategic planning and do not guarantee patient availability, enrollment, site performance, regulatory outcomes, or clinical success.